Stock listing

B3:N1VO34 Novo Nordisk A/S Ações

Brazilian listing (B3) of Novo Nordisk A/S · home listing Copenhagen:NOVOB

Follow Novo Nordisk A/S into a list and get an email when it puts out news.

Share price · BMFBOVESPA:N1VO34

27.79 BRL +0.39 (+1.4%)

Close on Nov 6, 2026

Day range
27.33 – 27.84 BRLNov 6, 2026
Volume
4,377 sharesNov 6, 2026
Market cap
981.1B BRLAt the close on Nov 6, 2026 · price × 35.30B shares outstanding
Novo Nordisk A/S logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE:NVO$40.31 USD+0.01 (0.0%)9,220,800$39.76$40.55$39.53$40.30Close on Nov 6, 2026
Xetra:NOV€36.16 EUR0.00 (0.0%)145,850€35.73€36.26€35.55€36.16Close on Nov 6, 2026
TSX:NOVO$17.58 CAD+0.15 (+0.9%)4,676$17.50$17.62$17.41$17.43Close on Nov 6, 2026
OTC:NONOF$40.00 USD0.00 (0.0%)335$39.74$40.00$39.74$40.00Close on Nov 6, 2026
Cboe Canada:NVON$4.40 CAD+0.04 (+0.9%)25,368$4.36$4.42$4.34$4.36Close on Nov 6, 2026
Frankfurt:NOV€36.10 EUR+0.36 (+1.0%)6,333€35.90€36.24€35.50€35.74Close on Nov 6, 2026
B3:N1VO3427.79 BRL+0.39 (+1.4%)4,37727.6827.8427.3327.40Close on Nov 6, 2026
Frankfurt:NOVA€36.02 EUR+0.38 (+1.1%)6,202€37.12€37.26€36.02€35.64Close on Nov 5, 2026
LSE:0TDD$40.36 USD+0.017 (0.0%)48,781$40.20$40.55$39.37$40.34Close on Nov 6, 2026
Dusseldorf:NOVA€36.28 EUR+0.46 (+1.3%)—€35.76€36.28€35.76€35.82Close on Nov 6, 2026
Hamburg:NOV€36.11 EUR-0.195 (-0.5%)150€35.79€36.16€35.75€36.30Close on Nov 6, 2026
Dusseldorf:NOV€36.28 EUR+0.435 (+1.2%)—€35.60€36.28€35.60€35.85Close on Nov 6, 2026
Munich:NOV€35.81 EUR-0.29 (-0.8%)523€35.76€35.81€35.76€36.10Close on Nov 6, 2026
Munich:NOVA€36.20 EUR+0.14 (+0.4%)25€35.96€36.20€35.96€36.06Close on Nov 6, 2026
Ticker
B3:N1VO34
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
B3
Currency
BRL

What changed lately

Calls

Replays

  • Novo Nordisk (Copenhagen:NOVO B) Q2 2026 Earnings Call

    Wed, Aug 05, 2026 · 7:00 AM ET

    Watch Transcript

  • Novo Nordisk (Copenhagen:NOVO B) Q1 2026 Earnings Call

    Wed, May 06, 2026 · 7:00 AM ET

    Watch Transcript

  • Novo Nordisk (Copenhagen:NOVO B) Q4 2025 Earnings Call

    Wed, Feb 04, 2026 · 7:00 AM ET

    Watch Transcript

Latest news

Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596

Sep 29, 2026

Highlights to be presented at Novo’s Capital Markets Day 2026

Sep 21, 2026

Novo Nordisk enters next chapter to bring better health to more people, supported by ‘Novo’ rebrand and updated corporate culture

Sep 14, 2026

Novo Nordisk A/S: IT Security incident at Novo Nordisk

Jun 11, 2026

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

Jun 11, 2026

Novo Nordisk introduces updated Rybelsus® tablet formulation in Canada for adults living with type 2 diabetes

Jun 9, 2026

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

Jun 3, 2026

Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association's 2026 Scientific Sessions

May 27, 2026

Novo Nordisk Introduces Extra Savings for Canadians Who Choose Ozempic®

May 26, 2026

Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke

May 26, 2026

All Novo Nordisk A/S news

Decks

Novo Nordisk A/S on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
92 in the last 12 months · 113 in all · newest Sep 29, 2026 · oldest 2025
Calls
26 calls with a replay · 26 with a transcript · latest Aug 5, 2026
Decks
230 decks · latest Sep 21, 2026

Where Novo Nordisk A/S is listed

ListingExchangeCountryCurrency
Copenhagen:NOVOB · Home listingCopenhagenDenmarkDKK
NYSE:NVONYSEUnited StatesUSD
Xetra:NOVXetraGermanyEUR
gettex:NOVgettexGermanyEUR
Tradegate:NOVTradegateGermanyEUR
TSX:NOVOTSXCanadaCAD
LS Exchange:A3EU6FLS ExchangeGermanyEUR
Aquis:NOVOBCAquisUnited KingdomDKK
SET:NOVOB80SETThailandTHB
gettex:NOVAgettexGermanyEUR
LSIN:0QIULSINUnited KingdomDKK
OTC:NONOFOTCUnited StatesUSD
BMV:NVONBMVMexicoMXN
Cboe Canada:NVONCboe CanadaCanadaCAD
Tradegate:NOVATradegateGermanyEUR
Stuttgart:NOVStuttgartGermanyEUR
Frankfurt:NOVFrankfurtGermanyEUR
Lang & Schwarz:A3EU6FLang & SchwarzGermanyEUR
B3:N1VO34 · This pageB3BrazilBRL
Cboe Canada:NOVOCboe CanadaCanadaCAD
BOATS:NVOBOATSUnited StatesUSD
GPW:NVOGPWPolandPLN
LS Exchange:866931LS ExchangeGermanyEUR
Aquis:NOVOBCAquisUnited KingdomDKK
Turquoise:NOVOBCTurquoiseUnited KingdomDKK
BMV:NOVOBNBMVMexicoMXN
Frankfurt:NOVAFrankfurtGermanyEUR
LSE:0TDDLSEUnited KingdomUSD
BX Swiss:NOVBX SwissSwitzerlandCHF
VIE:NNO2ViennaAustriaEUR
BX Swiss:NVOBX SwissSwitzerlandCHF
Aquis:NOVDAquisUnited KingdomEUR
Lang & Schwarz:866931Lang & SchwarzGermanyEUR
Dusseldorf:NOVADusseldorfGermanyEUR
BIVA:NOVOBNBIVAMexicoMXN
Hamburg:NOVHamburgGermanyEUR
Stuttgart:NOVAStuttgartGermanyEUR
Aquis:NOVDAquisUnited KingdomEUR
Frankfurt:NOV1FrankfurtGermanyEUR
BCBA:NVOBCBAArgentinaARS
Dusseldorf:NOVDusseldorfGermanyEUR
Hanover:NOVHanoverGermanyEUR
Munich:NOVMunichGermanyEUR
Munich:NOVAMunichGermanyEUR
Frankfurt:NOV0FrankfurtGermanyEUR
BSESOF:NOVBSESOFBulgariaEUR
Hamburg:NOVAHamburgGermanyEUR
BCBA:NVOCBCBAArgentinaUSD
BCBA:NVODBCBAArgentinaUSD
BCBA:NVO.CIBCBAArgentinaARS

Log in to ask 6ix AI your own questions about Novo Nordisk A/S.